ArticleHaematologica2020
Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 68 citations in OpenAlex.
- Homoharringtonine Promotes FTO Degradation to Suppress LILRB4-Mediated Immune Evasion in Acute Monocytic Leukaemia.Cell proliferation · 2026Article
- Article
- TET1: The epigenetic architect of clinical disease progression.Genes & diseases · 2025Review
- CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL/RPS transcription.Nature communications · 2025Article
- Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover.JCI insight · 2025Article
- Translating molecular insights into clinical success: alkaloid-based therapies for leukemia.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance.Frontiers in oncology · 2025Article
- Homoharringtonine: mechanisms, clinical applications and research progress.Frontiers in oncology · 2025Review
- Article
- Article
- Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation.Science advances · 2024Article
- Traditional Chinese medicine for acute myelocytic leukemia therapy: exploiting epigenetic targets.Frontiers in pharmacology · 2024Review
- Function and Regulation of the Calcium-Activated Chloride Channel Anoctamin 1 (TMEM16A).Handbook of experimental pharmacology · 2024Article
- NKD1 targeting PCM1 regulates the therapeutic effects of homoharringtonine on colorectal cancer.Molecular biology reports · 2023Article
- ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.Molecular oncology · 2023Article
- Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking.Leukemia · 2023Article
- Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia.Frontiers in pharmacology · 2023Review
- A case report of complete remission of acute myeloid leukemia combined withFrontiers in medicine · 2023Article
- Natural Products as Anticancer Agents: Current Status and Future Perspectives.Molecules (Basel, Switzerland) · 2022Review
- Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells.Nature communications · 2022Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 7 institutions in 3 countries.
Chenying LiDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Lei DongDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Rui SuDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Ying BiLudwig Institute for Cancer Research & Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Ying QingDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Xiaolan DengDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Yile ZhouDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Chao HuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Mengxia YuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Hao HuangDivision of Gynecologic Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Xi JiangDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Xia LiDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Xiao HeDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Dongling ZouDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Chao ShenDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Li HanDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Miao SunDepartment of Pediatrics, University of Cincinnati College of Medicine;Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Jennifer SkibbeDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Kyle FerchenDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Xi QinDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Hengyou WengDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Huilin HuangDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Chunxiao SongLudwig Institute for Cancer Research & Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jianjun ChenDepartment of Systems Biology & the Gehr Family Center for Leukemia Research, Beckman Research Institute of City of Hope, Monrovia, CA, USA jiej0503@zju.edu.cn jianchen@coh.org.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China jiej0503@zju.edu.cn jianchen@coh.org.
Beckman Research InstituteFirst Affiliated Hospital Zhejiang University · CNCity of Hope · USUniversity of Cincinnati · USLudwig Cancer Research · GBChina Medical University · CNUniversity of Cincinnati Medical Center · US
Funding
Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe function and underlying mechanism of TET1 in myelodysplastic syndromesR01DK124116 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2023
$2.2MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MPotential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role, mechanism and therapeutic potential of TET1 in MDSR56DK120282 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2018 to 2018
$100kNCI NIH HHS R01 CA178454NCI NIH HHS R01 CA182528NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS T32 CA117846NIDDK NIH HHS R01 DK124116NIDDK NIH HHS R56 DK120282
Abstract
Homoharringtonine, a plant alkaloid, has been reported to suppress protein synthesis and has been approved by the US Food and Drug Administration for the treatment of chronic myeloid leukemia. Here we show that in acute myeloid leukemia (AML), homoharringtonine potently inhibits cell growth/viability and induces cell cycle arrest and apoptosis, significantly inhibits disease progression
Indexed as
EpigenomeLeukemia, Myeloid, AcuteAnimalsCell Line, TumorDNADNA-Binding Proteinsfms-Like Tyrosine Kinase 3HomoharringtonineMiceProto-Oncogene ProteinsDNADNA-Binding Proteinsfms-Like Tyrosine Kinase 3HomoharringtonineProto-Oncogene ProteinsTET1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.